1. Whitney CG, Farley MM, Hadler J, et al. for the Active Bacterial Core Surveillance Program of the Emerging Infections Program network. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343:1917-1924.
2. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN; the Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother. 2003;52:229-246.
3. File TM, , Jr. Overview of community-acquired respiratory tract infections. In: Nightingale CH, Ambrose PG, File TM, Jr., eds. Community-Acquired Respiratory Infections: Antimicrobial Management. New York, NY: Marcel Dekker, Inc; 2003;1-30.
4. Ben-David D, Rubinstein E. Appropriate use of antibiotics for respiratory infections: review of recent statements and position papers. Curr Opin Infect Dis. 2002;15:151-156.
5. Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis. 2001;33:757-762.
6. Gwaltney JM, , Jr. Acute community-acquired sinusitis. Clin Infect Dis. 1996;23:1209-1225.
7. Niederman MS, Mandell LA, Anzueto A, et al. American Thoracic Society Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-1754.
8. Anon JB, Jacobs MR, Poole MD, et al. Sinus and Allergy Health Partnership Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. 2004;130:1-45.
9. Snow V, Mottur-Pilson C, Gonzales R. for the American College of Physicians-American Society of Internal Medicine Principles of appropriate antibiotic use for treatment of acute bronchitis in adults. Ann Intern Med. 2001;134:518-520.
10. Mandell LA, Bartlett JG, Dowell SF, File TM, , Jr, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003;37:1405-1433.
11. Gonzales R, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis: background. Ann Intern Med. 2001;134:521-529.
12. Bishai WR. I>ssues in the management of bacterial sinusitis. Otolaryngol Head Neck Surg. 2002;127:S3-S9.
13. Osguthorpe JD. Adult rhinosinusitis: diagnosis and management. Am Fam Physician. 2001;63:69-76.
14. Lindbaek M, Hjortdahl P, Johnsen UL. Use of symptoms, signs, and blood tests to diagnose acute sinus infections in primary care: comparison with computed tomography. Fam Med .1996;28:183-188.
15. Williams JW, Jr, Holleman DR, Jr, Samsa GP, Simel DL. Randomized controlled trial of 3 vs 10 days of trimethoprim/sulfamethoxazole for acute maxillary sinusitis. JAMA. 1995;273:1015-1021.
16. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
17. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest. 2000;117:380S-385S.
18. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117:398S-401S.
19. Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA. 1997;278:1440-1445.
20. Lonks JR. What is the clinical impact of macrolide resistance? Curr Infect Dis Rep. 2004;6:7-12.
21. Sokol W. Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 Respiratory Surveillance Program. Am J Med. 2001;111(suppl 9A):19S-24S.
22. Appelbaum PC. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis. 2002;34:1613-1620.
23. Doern GV, Brueggemann AB, Huynh H, Wingert E, Rhomberg P. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-1998. Emerg Infect Dis. 1999;5:757-765.
24. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect. 2004;48:56-65.
25. Pfaller MA, Jones RN. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections. Diagn Microbiol Infect Dis. 2002;44:77-84.
26. Hoban D, Waites K, Felmingham D. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study. Diagn Microbiol Infect Dis. 2003;45:251-259.
27. Dunbar LM. Current issues in the management of bacterial respiratory tract disease: the challenge of antibacterial resistance. Am J Med Sci. 2003;326:360-368.
28. Garau J. The hidden impact of antibacterial resistance in respiratory tract infection. Clinical failures: the tip of the iceberg? Respir Med. 2001;95(suppl A)-S5-11.
29. File TM, , Jr, Jacobs MR, Poole MD, Wynne B. 546, 547, 548, 549, 550, 551, 556, 557 and 592 Clinical Study Groups. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate. Int J Antimicrob Agents. 2002;20:235-247.
30. Amsden GW. Pneumococcal macrolide resistance: myth or reality? J Antimicrob Chemother. 1999;44:1-6.
31. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units. Implications for fluoroquinolone use. JAMA. 2003;289:885-888.
32. Brook I, Gooch WM 3rd, Jenkins SG, et al. Medical management of acute bacterial sinusitis. Recommendations of a clinical advisory committee on pediatric and adult sinusitis. Ann Otol Rhinol Laryngol Suppl. 2000;182:2-20.
33. Benninger MS, Sedory Holzer SE, Lau J. Diagnosis and treatment of uncomplicated acute bacterial rhinosinusitis: summary of the Agency for Health Care Policy and Research evidence-based report. Otolaryngol Head Neck Surg 2000;123:665-667.
34. Snow V, Mottur-Pilson C, Hickner JM. Principles of appropriate antibiotic use for acute sinusitis in adults. Ann Intern Med 2001;134:495-497.
35. Hickner JM, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for acute rhinosinustis in adults. Background. Ann Intern Med 2001;123:498-505.
36. Tankovic J, Bachoual R, Ouabdesselam S, Boudjadja A, Soussy CJ. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis . J Antimicrob Chemother. 1999;43 (suppl B):19-23.
37. Andrews JM, Weller TMA, Ashby JP, Walker RM, Wise R. The in vitro activity of ABT773, a new ketolide antimicrobial agent. J Antimicrob Chemother. 2000;46:1017-1022.
38. Cunha BA. Empiric therapy of community-acquired pneumonia: guidelines for the perplexed? Chest. 2004;125:1913-1919.
39. File TM, Jr, Garau J, Blasi F, et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 2004;125:1888-1901.
40. Maglio D, Nicolau DP. Antimicrobial efficacy review. Infect Dis. 2004;7:33-36.
41. Sobol SE, Schloss MD, Tewfik TL. Sinus, acute, medical treatment. Available at:http://www.emedicine.com/ENT/ topic337.htm Accessed January 4, 2005.
42. Tse J, Cosep ML, Aminimanizani A, Gill MA. Communityacquired pneumonia. California Pharmacist Winter. 2002;2003:54-65.
43. Full US Prescribing Information for Ketek Available at: http://www.aventis-US.com/PIs/ketek_TXT.html Accessed January 4, 2005.
44. Full US Prescribing Information for Avelox Available at: http://www.univgraph.com/bayer/inserts/Avelox.pdf .Accessed January 4, 2005.
